Pfizer Inc (NYSE:PFE) Announces Results Of Two Phase-III Clinical Trials

Posted by Nathan Alexander October 14, 2013 0 Comment 2453 views

Last week, Pfizer Inc. (NYSE:PFE) announced top line results from 2 different Phase-III clinical trials of the novel oral Janus kinase-inhibitor, tofacitinib. This is being investigated to be used for treating adults who suffer from moderate to severe chronic plaque-psoriasis. These are the first 2 of the 5 different studies that are part of the Phase-III OPT Program. This is one of the most extensive global clinical-trails that is being conducted to investigate moderate to severe chronic-plaque psoriasis, to date.

The results for these trials are expected to come in by the 2014 Q2. These 4 studies along with the long term extension-study will be the strong base for the potential psoriasis-submission to the regulatory authorities.

Friday’s trading

In Friday’s trading, Pfizer Inc (NYSE:PFE) dropped by 0.17%. The shares opened at a price of $28.92, which rose to an intraday high of $28.93 and dropped to a close of $28.72. Approximately 24.40M shares were traded on Friday while an average volume of 25.04 million shares were traded over a period of 30 days. The 52-week low of Pfizer Inc (NYSE:PFE) shares is $23.55 and its 52-week high is $31.15. Pfizer Inc (NYSE:PFE) has a market capitalization of $190.14 billion.

About the company

Pfizer Inc (NYSE:PFE) is a research based, global bio-pharma company. It has five operating segments – 1) Primary Care; 2) Specialty Care and Oncology;3) Established Products and Emerging Markets; 4) Animal Health and Consumer Healthcare, and 5) Nutrition. Its diversified global-healthcare portfolio includes various human & animal biologic and small-molecule vaccines and medicines. It also includes nutritional products and consumer-healthcare products. The Animal Health business-unit is involved in discovering, developing and selling products that are used in the treatment and prevention of diseases in companion animals and livestock. On 1 August 2011, Pfizer Inc (NYSE:PFE) completed its Capsugel business-sale.

About Nathan Alexander

Nathan Alexander holds bachelor’s degrees in Journalism and European Studies from Boston University. Nathan reports round up the day’s business and financial market news and include keynote interviews with major business players and updates on Asian, European and US stock markets. He has interviewed heads of leading European banking institutions such as European Central Bank President Jean-Claude Trichet and HSBC Chairman Stephen Green, and CEOs from the business world including Microsoft founder Bill Gates, Virgin Chairman Sir Richard Branson and former Porsche President and CEO Dr Wendelin Wiedeking.

View all post by Nathan Alexander Visit author's website

Write Your Comment